Monitoring & Long-Term Health

Because Familial Partial Lipodystrophy Type 3 (FPLD3) involves lifelong metabolic challenges, protecting your long-term health depends on a consistent, individualized surveillance schedule. Unlike standard health checks, monitoring for FPLD3 must be more frequent and detailed to catch metabolic changes before they cause permanent organ damage ^[1].

The Annual Check-Up: Your Minimum Requirement

International guidelines for lipodystrophy recommend that, at a minimum, you undergo comprehensive screening every year ^[1]. This annual review should cover five key areas:

1. Metabolic Health: Checking your HbA1c (average blood sugar) and a full fasting lipid panel (triglycerides, HDL, and LDL cholesterol). The frequency of HbA1c checks may increase depending on your actual control ^[1][2].
2. Liver Health: Testing liver enzymes (ALT and AST) to check for inflammation ^[1][3]. Note that having “normal” ALT/AST does not completely rule out liver disease in lipodystrophy.
3. Kidney Health: Assessing your eGFR (kidney function) and testing your urine for protein (albuminuria) ^[1][4].
4. Heart Health: Measuring your blood pressure and assessing your overall cardiovascular risk ^[1][5].
5. Standard Diabetes Care: If you have diabetes, surveillance must also include an annual dilated retinal (eye) exam, a comprehensive foot and neuropathy assessment, and individualized dental care and vaccinations.

Protecting Your Pancreas: Tracking Triglycerides

While annual checks are the baseline, people with FPLD3 often need to check their triglycerides more often, especially if their levels are above 500 mg/dL ^[6][7].

• The Pancreatitis Threshold: The goal of monitoring is to keep triglycerides below the level where they can cause acute pancreatitis (inflammation of the pancreas). This is a medical emergency characterized by severe abdominal pain ^[8].
• Adjustment Periods: If you are changing your diet or starting a new medication (like a fibrate or omega-3), your doctor may want to check your lipids every 4 to 12 weeks until they stabilize ^[1].

Liver Surveillance: Beyond Simple Blood Tests

Because FPLD3 causes fat to build up in the liver (hepatic steatosis), standard liver enzyme tests (ALT/AST) may not tell the whole story ^[5].

• Imaging: Your doctor may recommend a liver ultrasound or a specialized MRI (such as MR-PDFF) to measure exactly how much fat is in the liver ^[9][10].
• Fibrosis Screening: In some lipodystrophy cohorts, about 30% of women developed significant liver scarring (fibrosis), though individual risks vary ^[11]. A test called transient elastography (FibroScan) uses sound waves to measure liver stiffness and can help determine if the fat buildup is causing permanent damage ^[11].

Kidney and Heart Protection

• Kidney Monitoring: FPLD3 can sometimes affect the kidneys, leading to proteinuria (protein in the urine) ^[4][12]. An annual urine test called a uACR (urine albumin-to-creatinine ratio) is the best way to catch early signs of kidney strain before your blood work changes ^[1][4].
• Heart and Arteries: People with FPLD3 have a higher risk of early-onset heart disease and high blood pressure ^[6][5]. In one study, roughly 17% of patients had coronary artery disease ^[6]. Your doctor should regularly assess you for signs of heart disease and may use specialized imaging, like a stress test or coronary calcium score, based on your individualized symptoms and risk profile ^[13].

When to Increase Monitoring

Routine annual monitoring is for when your health is stable. You will need more frequent checks if you:

• Are planning a pregnancy or are currently pregnant ^[14].
• Are starting a specialized treatment like metreleptin ^[3].
• Have triglycerides that are rapidly rising or are consistently above 1,000 mg/dL ^[8].
• Have been diagnosed with MASLD/MASH (steatohepatitis) ^[15].